NYSE:NVO - Novo Nordisk A/S Stock Price, Forecast & News

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk A/S declared a semi-annual dividend on Friday, February 7th. Stockholders of record on Monday, March 30th will be given a dividend of $0.7874 per share on Tuesday, April 7th. This represents a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, March 27th. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.32. View Novo Nordisk A/S's Dividend History.

Novo Nordisk A/S (NYSE:NVO) released its quarterly earnings data on Friday, November, 1st. The company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.62 by $0.02. The company earned $4.51 billion during the quarter, compared to analysts' expectations of $4.55 billion. Novo Nordisk A/S had a net margin of 31.95% and a return on equity of 73.70%. View Novo Nordisk A/S's Earnings History.

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Friday, May 1st 2020. View Earnings Estimates for Novo Nordisk A/S.

Novo Nordisk A/S issued an update on its FY 2020 IntraDay earnings guidance on Wednesday, February, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $18.852-19.401 billion, compared to the consensus revenue estimate of $18.74 billion.

9 brokerages have issued 1 year price targets for Novo Nordisk A/S's shares. Their forecasts range from $51.85 to $400.00. On average, they anticipate Novo Nordisk A/S's share price to reach $214.82 in the next year. This suggests a possible upside of 269.5% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.

Headlines about NVO stock have trended very negative recently, according to InfoTrie. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Novo Nordisk A/S earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for Novo Nordisk A/S.

Novo Nordisk A/S saw a increase in short interest in February. As of February 14th, there was short interest totalling 6,040,000 shares, an increase of 17.1% from the January 30th total of 5,160,000 shares. Based on an average trading volume of 1,430,000 shares, the days-to-cover ratio is currently 4.2 days. Currently, 0.3% of the shares of the stock are sold short. View Novo Nordisk A/S's Current Options Chain.

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Pfizer (PFE), Abbott Laboratories (ABT), AbbVie (ABBV), Eli Lilly And Co (LLY), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T), QUALCOMM (QCOM), Starbucks (SBUX), Alibaba Group (BABA) and Cisco Systems (CSCO).

Novo Nordisk A/S's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.11%), Loomis Sayles & Co. L P (0.92%), Bank of America Corp DE (0.48%), State Street Corp (0.19%), Everett Harris & Co. CA (0.13%) and Sustainable Growth Advisers LP (0.11%). View Institutional Ownership Trends for Novo Nordisk A/S.

NVO stock was sold by a variety of institutional investors in the last quarter, including Sustainable Growth Advisers LP, Bank of America Corp DE, State Street Corp, NorthCoast Asset Management LLC, Credit Suisse AG, Alyeska Investment Group L.P., Hikari Power Ltd and Boston Partners. View Insider Buying and Selling for Novo Nordisk A/S.

NVO stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, First Trust Advisors LP, Loomis Sayles & Co. L P, Capital International Investors, Amundi Pioneer Asset Management Inc., Bain Capital Public Equity Management II LLC, Connor Clark & Lunn Investment Management Ltd. and Beacon Investment Advisory Services Inc.. View Insider Buying and Selling for Novo Nordisk A/S.

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVO stock can currently be purchased for approximately $58.13.

Novo Nordisk A/S has a market capitalization of $137.65 billion and generates $18.30 billion in revenue each year. The company earns $5.84 billion in net income (profit) each year or $2.46 on an earnings per share basis. Novo Nordisk A/S employs 43,258 workers across the globe.View Additional Information About Novo Nordisk A/S.

The official website for Novo Nordisk A/S is http://www.novonordisk.com/.

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]